Takeda Pharmaceutical (TAK) FCF Margin (2018 - 2026)

Takeda Pharmaceutical's FCF Margin history runs 9 years deep, the most recent figure standing at 5.35% for Q1 2026.

• On a quarterly basis, FCF Margin rose 546.0% year-over-year to 5.35% in Q1 2026; TTM through Mar 2026 was 15.12%, a 293.0% increase from a year earlier, with the FY2026 full-year figure at 23.04%, up 435.0% from the prior year.
• FCF Margin slipped to 5.35% in Q1 2026 per TAK's latest filing, from 37.91% in the prior quarter.
• Across five years, FCF Margin topped out at 40.71% in Q4 2024 and bottomed at 10.81% in Q1 2025.
• The 5-year median for FCF Margin is 13.07% (2023), against an average of 15.2%.
• Across the five-year window, FCF Margin sank 1913 bps in 2023 and soared 2229 bps in 2024, its largest moves.
• Year by year, FCF Margin stood at 37.54% in 2022, then plunged by 51 bps to 18.42% in 2023, then surged by 121 bps to 40.71% in 2024, then decreased by 7 bps to 37.91% in 2025, then tumbled by 114 bps to 5.35% in 2026.
• Per Business Quant, the three latest TAK FCF Margin figures stand at 5.35% (Q1 2026), 37.91% (Q4 2025), and 11.86% (Q3 2025).